Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...

Genentech, a member of the Roche Group, has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Group, announced that the Phase 3 MUSETTE trial comparing a high dose of Ocrevus intravenous infusion to the currently approved Ocrevus IV 600 mg dose in people with relapsing multiple sclerosis did ...

Convelo Therapeutics Inc. and Genentech Inc. have identified lanosterol 14α-demethylase (CYP51A1; CYP51) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, ...

Lonza, the Swiss Biotech firm that purchased Vacaville’s Genentech plant from Roche in 2024, released a streamlined operating model and invitations to its Annual General Meeting in Basel, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial ...

An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease.

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Carlos Garcia was on the SSF Bay Trail when he captured this gorgeous image of the sun rising over the silky smooth waters of ...